MTOR and cancer: In particular, the PI3K/AKT/mTOR (phosphoinositide 3-kinase/protein kinase B/ mammalian (or mechanistic) target of Rapamycin) was found to be hyperactivated in almost all malignant neoplasms [6] with a prevalence ranging from 40% to 90%, thus rendering it an appealing target for cancer treatment [7].